http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170091359-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_786a56ad85ce19f17c6277181165e423 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-12 |
| filingDate | 2016-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f49ec754441c204ce4c3f71de7af2511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_852be6f68c297f97c8c724f813fdf8e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b9d7c0c7c1854d3b1887164fb6969f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e627f18d046069c134d26acda62e1168 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c3b9407455d4f03305d6bf895d4a631 |
| publicationDate | 2017-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170091359-A |
| titleOfInvention | Novel Therapeutic Agents For Gastro-Esophageal Reflux Disease |
| abstract | The present invention relates to a novel therapeutic agent for gastroesophageal reflux diseases, and more specifically, to a pharmaceutical composition capable of effectively preventing and treating gastroesophageal reflux diseases by comprising montmorillonite powder as an active ingredient. The pharmaceutical composition of the present invention, due to having montmorillonite powder as its active ingredient, can suppress the actions of pancreatic protease and pepsin departed from a stomach, and the pharmaceutical composition has excellent safety, and is not absorbed in the human body, and thus can effectively prevent and treat gastroesophageal reflux diseases without concerns about side effects. Also, the montmorillonite powder, compared to pre-existing therapeutic agents for gastroesophageal reflux diseases, is easy to be produced and cost-effective, and thus the pharmaceutical composition of the present invention can be beneficially used to supply patients with gastroesophageal reflux diseases with an effective therapeutic agent reliably at a low price. |
| priorityDate | 2016-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.